Ecovyst heads into its third-quarter report with a split personality. Management has raised its full-year outlook two quarters running and folded the newly closed Calabrian acquisition into the numbers, yet the stock has dropped 18.5% since the last report, trailing the S&P 500 by nearly 18 percentage points. The November 5 release, due before the open, is the first quarter with Calabrian fully on the books. It should show whether the confident tone of the summer call holds up or whether the market's skepticism about sulfur pricing and virgin acid volume is justified.

The Street expects earnings of $0.18 per share, flat with a year ago, on revenue of $297.5 million, up about 45%. That gap between sales and profits is the key to reading the quarter. Much of the top-line jump reflects Calabrian and sulfur cost pass-through, which management now pegs at roughly $220 million for the year, up from about $155 million last spring. Pass-through inflates revenue without adding much profit, so the headline sales figure says less about the business than adjusted EBITDA and margins do.

The guidance math gives a clearer bar. Ecovyst lifted its 2026 adjusted EBITDA target to $195 million to $207 million, including $10 million to $12 million from Calabrian in the second half, and raised the floor on the legacy business to $185 million. With $93 million already booked in the first half, the remaining two quarters must deliver roughly $102 million to $114 million. Management has flagged higher fourth-quarter turnaround costs and softer fourth-quarter pricing, excluding pass-through, so the third quarter likely has to carry more than half of that load. A result clearly above the $53 million posted in the second quarter would support the raised outlook. A flat or weaker figure would raise questions about the back half. Full-year consensus of $0.66 per share sits just above the midpoint of the $0.58 to $0.72 range. Revenue consensus of $976.8 million still trails the raised $1.02 billion to $1.06 billion sales guide, which suggests some estimates have not fully caught up with the acquisition.

Operationally, regeneration services are the anchor. Last quarter management pointed to high refinery utilization, favorable alkylation economics and far fewer unplanned customer outages than in the disruption-heavy 2025. Continued strength there would confirm that the base business is compounding. Virgin sulfuric acid is the softer spot. Management said second-half volume would run slightly below 2025 as spot opportunities fade, even with double-digit growth from Wagamon and mining demand tied to copper and electrification. Any sign that customers are cutting purchases ahead of expected sulfur price declines would make the destocking risk management raised a near-term problem. Investors should also look for early evidence that the $3 million to $4 million in Calabrian synergies is on track, along with updates on the Gulf Coast logistics expansion.

The balance sheet is a secondary theme. Leverage rose to 2.0 times from 1.2 times on $100 million of acquisition debt, and the capital spending guide climbed to $85 million to $95 million. A quarter of Calabrian cash flow should begin pulling leverage back down. Holding the $45 million to $55 million free cash flow target would reassure holders worried about the higher spending.

Sentiment has swung from roughly neutral before the last report to firmly bearish. At $9.97, the stock sits well below its 200-day moving average of $11.82 and only modestly above its post-earnings low of $9.56. The entire range since the last report sits below the prior quarter's trough of $11.62, so the market is plainly discounting the raised guidance. In the end, the report turns on one question: does the legacy business plus Calabrian produce enough third-quarter EBITDA to make the second-half target look achievable despite plateauing sulfur and thinner spot volume? A reaffirmed outlook backed by a strong quarter would challenge the bearish setup. Another trim to volume expectations would suggest the selloff saw it coming.